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The Fanconi anemia (FA) pathway, of which the FANCD2 protein is a key component, plays crucial
roles in the maintenance of hematopoietic stem cells and suppression of carcinogenesis. However,
the function of FANCD2 remains unclear. Here, we report that FANCD2 is a novel and speciﬁc sub-
strate of caspase 3. Cleavage of FANCD2 by caspase 3 did not require either the FA core complex
or mono-ubiquitylation of FANCD2, and was stimulated by p53. In addition, we identiﬁed the cleav-
age sites and generated cell lines that stably express a caspase-resistant FANCD2 mutant. Our data
suggest that FANCD2 is regulated by caspase-mediated degradation during apoptosis induced by
DNA damage.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/3.0/).1. Introduction
Fanconi anemia (FA) is a rare genetic disorder associated with
bone marrow failure, multiple skeletal malformations, and cancer
susceptibility [1]. At the cellular level, FA is characterized by gen-
ome instability and hypersensitivity to DNA interstrand crosslinks
(ICL) induced by chemotherapeutic platinum compounds (e.g., cis-
platin) and bifunctional alkylating agents, such as mitomycin C
(MMC). To date, 16 FA genes have been identiﬁed, and all of the
encoded proteins function in an intracellular signaling pathway,
the FA pathway, which regulates responses to and repair of ICL
damage [2,3]. Recent studies have suggested that the FA pathway
counteracts DNA damage induced by endogenous aldehydes in
hematopoietic stem cells [4,5]. Eight of the FA gene products and
other non-FA proteins associate with each other, forming the FA
core complex [2,3]. Upon ICL damage, the FA core complex is
loaded onto damaged chromatin [6], where it functions as a
multi-subunit E3 ubiquitin ligase to mono-ubiquitylate both
FANCD2 and FANCI proteins, which form a heterodimeric complex
(ID complex) [2,3]. This mono-ubiquitylation step is a critical event
in the FA pathway [7,8], because the mono-ubiquitylated ID
complex is loaded at damaged sites by binding to aberrant DNAstructures, where it forms subnuclear foci and orchestrates DNA
repair [2,3,9].
The FA pathway is inactivated in a wide variety of human can-
cers through hyper-methylation of the promoter sequence of one
of the FA genes, FANCF [10–13]. This inactivation causes cisplatin
sensitivity, suggesting that the FA pathway plays a broad and
important role in genome maintenance and prevention of carcino-
genesis. Furthermore, reactivation of the FA pathway can contrib-
ute to acquired resistance to cisplatin in cancer cells [14,15].
These ﬁndings indicate that the integrity of the FA pathway is an
important determinant of cellular responses to chemotherapy
based on ICL-inducing compounds, which are widely used as
anti-cancer drugs. The mechanism of action of those chemothera-
peutic agents involves covalent binding to purine DNA bases, lead-
ing primarily to programmed cell death (apoptosis) [16]. During
apoptosis, the caspase family of cysteine proteases is activated,
and these factors mediate endolytic cleavage of many protein sub-
strates. Regardless of what triggers the signal, apoptotic cells
develop a characteristic morphology, including DNA fragmentation
and loss of mitochondrial membrane potential. These changes are
largely mediated by cleavage of caspase substrates. A large number
of caspase substrates have been identiﬁed so far [17], and the list
continues to grow. Many DNA damage response (DDR) proteins,
such as BRCA1, CHK1, MDC1, MLH1, and RAD51, are caspase
substrates [18–23], raising the possibility that cleavage of DDR
proteins is critical for execution of apoptosis.
Fig. 1. DNA damage induces FANCD2 cleavage in a caspase-dependent manner. Whole-cell extracts were subjected to immunoblotting with the indicated antibodies. (A)
HeLa cells were incubated for 24 h after irradiation with various doses of UV (10, 20, and 40 J/m2). In addition, HeLa cells were continuously exposed for 24 h to different
concentrations of cisplatin (CDDP; 25, 50, and 100 lM) and methyl methanesulfonate (MMS; 125, 250, and 500 mM). D2-L: mono-ubiquitylated form, D2-S: non-
ubiquitylated form, D2-XS: shorter form(s) of FANCD2. (B) FANCD2-deﬁcient PD20F cells (parental) were infected with retrovirus expressing EGFP-tagged wild-type FANCD2
(+EGFP-wtD2) or a control virus derived from the empty vector (+vec). Stably transformed cells were selected and cultured for 24 h after irradiation with UV (20 J/m2). (C)
PD20F cells stably expressing EGFP-FANCD2 were treated with or without UV (20 J/m2). After 12 h incubation, lactacystin (Lact, 5 lM) and/or z-VAD-fmk (zVAD, 10 lM) were
added to culture medium as indicated, and the cells were incubated for an additional 12 h. For lane 9, cells were treated with staurosporine (STS, 1 lM) for 6 h. Anti-a-tubulin
(TUBA) is shown as a loading control.
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pathway, is a novel and speciﬁc substrate of caspase 3 that is acti-
vated during apoptosis induced by DNA damage. This cleavage
does not depend on either the functional FA core complex or
mono-ubiquitylation of FANCD2, and it is stimulated by the tumor
suppressor p53. Furthermore, we show that a mutant FANCD2 that
is resistant to caspase cleavage exerts normal functions in DNA
repair, except for formation of damage-induced nuclear foci, and
does so without signiﬁcantly affecting apoptosis.
2. Materials and methods
2.1. Cell cultures and chemicals
The FA-deﬁcient cell lines were grown in DMEM supplemented
with 15% FBS. The other cells were all grown in DMEM supple-
mented with 10% FBS. Cisplatin (P4394), z-VAD-fmk (C2105), and
methyl methanesulfonate (129925) were purchased from Sigma–
Aldrich. Lactacystin (426102) and staurosporine (569396) werepurchased from Calbiochem. Mitomycin C was purchased from
Nacalai Tesque (20898-21).
2.2. Immunoblotting, immunoprecipitation and immunoﬂuorescence
Immunoblotting, immunoprecipitation and immunoﬂuores-
cence were performed as described in the Supplemental data.
2.3. Retroviral infection
Production of pMMP retroviral supernatants and infection of
cells were performed as previously described [24].
2.4. Site-directed mutagenesis
Site-directed mutations were introduced with the QuikChange
Site-Directed Mutagenesis Kit (Agilent Technologies). The muta-
tions were veriﬁed using the BigDye Terminator v3.1 Cycle
Sequencing Kit and the 3130 Genetic Analyzer (Life Technologies).
Fig. 2. Cell-free caspase assay recapitulates the cleavage of FANCD2. Aliquots of whole-cell extract from WI38 VA13 cells were incubated individually with active forms of
recombinant caspases in the presence or absence of z-VAD-fmk (50 lM). After the incubation, the reactions were subjected to immunoblotting with the anti-FANCD2
antibody. Ponceau S staining is shown as a loading control.
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Cell-free caspase assays were carried out with solutions and
enzymes, which were all purchased from BioVision. Whole-cell
extract was prepared using Cell Lysis Buffer (1067-100). Aliquots
of the lysate were incubated for 1 h at 37 C with active forms of
individual recombinant caspases (K233-10-25) in 1 Reaction
Buffer (1068-20).
2.6. shRNA expression
All shRNAs were expressed using the pSIREN-RetroQ system
(Takara Bio). The individual shRNA constructs were designed using
the RNA Target Sequence Selector (Takara Bio). Each sequence is
shown in Supplemental data.
2.7. Mitomycin C sensitivity assay
Cells were seeded onto 10 cm dishes (500 cells/dish). After
overnight culture, cells were treated with the indicated concentra-
tions of MMC for 24 h. After washing with phosphate-buffered
saline (PBS), cells were cultured in normal medium for 10–14 days.
The resultant colonies were visualized by ﬁxation and staining
with 1% crystal violet. Only colonies with more than 50 cells were
scored.
3. Results
3.1. FANCD2 is cleaved by caspases during apoptosis
The FANCD2 protein is mono-ubiquitylated upon DNA damage
[7]. Consistent with this notion, in HeLa cells cultured under nor-
mal conditions, immunoblot analyses mainly revealed non-ubiqui-
tylated FANCD2 (FANCD2 short form: D2-S), whereas mono-
ubiquitylated FANCD2 (FANCD2 long form: D2-L) was induced by
treatment with various genotoxic stresses (Fig. 1A). However,
particularly with relatively high doses of DNA damage, we
observed attenuation of both forms of FANCD2 and simultaneous
appearance of new bands with higher mobility that reacted withanti-FANCD2 antibody (D2-XS). These bands were observed irre-
spective of the DNA-damaging agent employed and at relatively
low doses of these agents (Fig. 1A). However, high doses of DNA-
damaging agents were used to facilitate the detection of cleavages.
To conﬁrm that these smaller polypeptides were indeed derived
from FANCD2, we stably expressed EGFP-tagged FANCD2 in the
FANCD2-deﬁcient cell line, PD20F. After treatment with a relatively
high dose of ultraviolet light (UV), we observed a similar pattern of
high-mobility bands that reacted with anti-GFP antibody (Fig. 1B,
lane 6), indicating DNA damage-induced cleavage of FANCD2. A
pan-caspase inhibitor, z-VAD-fmk, suppressed the appearance of
the shorter species of FANCD2 (Fig. 1C, lanes 5 and 6), whereas a
proteasome inhibitor, lactacystin, slightly increased the levels of
this species (Fig. 1C, lanes 3 and 4, and Fig. S1). Notably, simulta-
neous treatment with z-VAD-fmk and lactacystin suppressed UV-
induced cleavage of FANCD2 (Fig. 1C, lanes 7 and 8) as well as
treatment with z-VAD-fmk alone. When the shorter forms of
FANCD2 were detectable, the active forms of caspase 3 and 7 were
also observed (Fig. 1C), indicating that extensive DNA damage had
induced apoptosis in these cells. Treatment with the pan-kinase
inhibitor staurosporine (known to be an apoptosis inducer) also
induced the same pattern of shorter forms of FANCD2 (Fig. 1C, lane
9). These results indicate that the FANCD2 protein is cleaved by
caspases during apoptosis upon relatively high levels of DNA
damage.
3.2. FANCD2 is cleaved speciﬁcally by caspase 3
To identify the caspase responsible for the FANCD2 cleavage, we
carried out cell-free caspase assays using active forms of recombi-
nant caspases. Whole-cell extracts from normal human ﬁbroblasts
(without treatment with DNA-damaging agents) were incubated
individually with each of recombinant caspases. Immunoblot anal-
yses of endogenous FANCD2 in the extract revealed that caspases
1, 3, 6, 7, and 8 could cleave FANCD2 (Fig. 2). Those cleavages were
completely suppressed in the presence of z-VAD-fmk. In particular,
the cleavage pattern by caspase 3 seemed almost the same as that
observed in vivo. To conﬁrm this notion in vivo, we depleted cas-
pase 3 in HeLa cells using shRNA. As shown in Fig. 3A, depletion
Fig. 3. Caspase 3 is responsible for FANCD2 cleavage. HeLa cells (parental) were
infected with retroviruses expressing shRNA targeting caspase 3 (A) and caspase 7
(B), respectively. For each caspase, two shRNA constructs (#1 and #2) were
generated. As controls, virus expressing shRNA against luciferase (Luci) or virus
derived from the empty vector (Ctrl) was used. Following UV irradiation (20 J/m2)
or mock irradiation, the cells were incubated for 24 h. Whole-cell extracts were
subjected to immunoblotting with the indicated antibodies. (C) MCF-7 cells were
treated with various DNA-damaging agents, and whole-cell extracts were subjected
to immunoblotting with the indicated antibodies, exactly as in Fig. 1A. Treatment
with STS was carried out as in Fig. 1C.
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(lanes 5 and 6), whereas depletion of caspase 7 had only a marginal
effect (Fig. 3B, lanes 5 and 6). Furthermore, the breast cancer cell
line MCF-7, which lacks caspase 3 [25,26], did not exhibit detect-
able FANCD2 cleavage after treatment with any DNA-damaging
agent, despite the presence of the active form of caspase 7
(Fig. 3C). Together, these results indicate that FANCD2 is cleaved
speciﬁcally by caspase 3.
3.3. Effect of the FA core complex and p53 on FANCD2 cleavage
In response to DNA damage, mono-ubiquitylation of FANCD2 is
mediated by the FA core complex. This post-translational modiﬁca-
tion of FANCD2 is important for downstream events in the FA path-
way [7]. To determine whether the FA core complex is required for
FANCD2 cleavage, we took advantage of cell lines lacking func-
tional FANCA, FANCC, or FANCF, all of which are essential compo-
nents of the FA core complex. When these cells were treated with a
relatively high dose of cisplatin, FANCD2 cleavage was observed in
all cell lines (Fig. 4A). Although the mono-ubiquitylation of
FANCD2 could be restored in these cells by expression of the corre-
sponding wild-type FA genes, FANCD2 cleavage was not affected
by this functional complementation. Furthermore, mutation at
the mono-ubiquitylation site in FANCD2 (K561R) had no effect
on cleavage (Fig. 4B). These results indicate that the FA core com-
plex and mono-ubiquitylation of FANCD2 are dispensable for
FANCD2 cleavage.
Upon DNA damage and other types of cellular stresses, the
tumor-suppressor protein p53 regulates key processes, including
DNA repair, cell-cycle arrest, and apoptosis [27]. To investigate
the roles of p53 in FANCD2 cleavage, we analyzed a pair of
HCT116 cell lines with either wild-type or disrupted p53 genes
[28]. In the cell line with intact p53, DNA damage induced stabil-
ization and robust accumulation of p53 (Fig. 5). Concomitant with
accumulation of p53, we detected a reduction in the level of full-
length FANCD2 (both L and S forms) and the appearance of its
cleavage products (XS form). On the other hand, the cognate
p53-deﬁcient cell line was less able to induce FANCD2 cleavage,
even in the presence of extensive DNA damage (Fig. 5, lanes 5–8
and lanes 13–16). These results indicate the possibility that func-
tional p53 promotes DNA damage–induced apoptosis and the
FANCD2 cleavage.
3.4. Mapping of FANCD2 cleavage sites
Caspases share speciﬁcity for the amino-acid sequences at
cleavage sites of target proteins, typically cleaving at the car-
boxyl-terminal side of the last aspartic acid in the tetra-peptide
sequences x-x-x-D or D-x-x-D [26]. Based on the pattern of the
cleavage products (D2-XS), we hypothesized that FANCD2
possesses at least four target sites for caspase 3. To determine
the cleavage sites, we performed site-directed mutagenesis to
introduce D-to-A mutations at several predicted candidate sites
in the FANCD2 sequence. These mutant FANCD2 genes were tagged
with EGFP, and the resultant fusion protein was stably expressed in
the FANCD2-deﬁcient PD20F cell line. As shown in Fig. 6, a change
in any one of four aspartic acids (D667, 693, 753, and 1046) abol-
ished one of the major cleavage products of FANCD2, whereas the
D662A mutation had no effect. Next, we simultaneously intro-
duced all four relevant D-to-A mutations in the FLAG-tagged
FANCD2 sequence, which was stably expressed in the FANCD2-
deﬁcient PD20F cell line. We conﬁrmed that the quadruple (4DA)
mutations in FANCD2 conferred almost complete resistance to
DNA damage-induced cleavage (Fig. 7A).
Fig. 4. FANCD2 cleavage is independent of the FA core complex and its mono-ubiquitylation activity. (A) Three FA-deﬁcient cell lines, GM6914 (FA-A), PD426F (FA-C), and
TOV-21G (FANCF-inactivated ovarian cancer), as well as the corresponding complemented cell lines, were treated with various concentrations of cisplatin for 24 h. (B) Either
wild-type FANCD2 (+wtD2) or K561R (mono-ubiquitylation site) mutant FANCD2 was stably expressed in PD20F cells, which were treated with the indicated concentrations
of cisplatin for 24 h. Whole-cell extracts were subjected to immunoblotting with the indicated antibodies.
Fig. 5. p53 stimulates FANCD2 cleavage. A p53-proﬁcient HCT116 cell line (WT) and a derivative line in which p53 was knocked out (KO) were cultured for 24 h after
irradiation with the indicated doses of UV, or cultured for 24 h with continuous exposure to the indicated concentrations of cisplatin. Whole-cell extracts were subjected to
immunoblotting with the indicated antibodies.
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Fig. 6. Determination of cleavage sites in FANCD2. The aspartic acid at each putative caspase target site was changed to alanine, and the resultant mutants were stably
expressed as EGFP fusion proteins in the PD20F cell line. Cells were treated with/without continuous exposure to cisplatin (40 lM) for 24 h. Whole-cell extracts were
subjected to immunoblotting with the indicated antibodies.
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To examine the effect of cleaved FANCD2, a cell line expressing
a C-terminal truncated form of FANCD2 was generated. However,
expression of the truncated form had no effect on the cell survival
of the parental PD20F cell line (Fig. S2). Furthermore, to assess the
function of FANCD2 cleavage, we compared the DDR of cell lines
stably expressing caspase-resistant FANCD2 with that of a control
cell line expressing wild-type FANCD2. Both cell lines exhibited
FANCD2 mono-ubiquitylation in response to cisplatin treatment
(Fig. 7A), resistance to mitomycin C (MMC) (Fig. 7B), and interac-
tion between FANCD2 and FANCI (Fig. 7C). In addition, as shown
in Fig. 7D, the two cell lines expressing wild-type or mutant
FANCD2 exhibited similar apoptotic responses to cisplatin treat-
ment, judging from cleavage of PARP1 and caspase 3. These results
indicate that the absence of FANCD2 cleavage did not affect ICL
damage repair or apoptosis induction in these cells. Surprisingly,
however, we noticed that the DNA damage-induced formation of
nuclear foci was compromised in cells expressing the caspase-
resistant mutant FANCD2, which was mostly diffusely distributed
in the nucleus irrespective of the presence or absence of DNA dam-
age (Fig. 7E and S3). These results not only indicate the importance
of these aspartate residues in regulating the subnuclear localiza-
tion of FANCD2, but also suggest the possibility of uncoupling
the functions of FANCD2 in nuclear foci formation and DNA repair.
4. Discussion
In this study, we demonstrated that a member of the FA
proteins, FANCD2, is cleaved speciﬁcally by caspase 3 at four or
more sites during apoptosis. Although previous studies reported
caspase-mediated regulation of FA proteins [29,30], this is the ﬁrst
study to identify both a speciﬁc caspase in and the cleavage sites
within the FA proteins.
Following DNA damage, FANCD2 is regulated by post-transla-
tional modiﬁcation [7]. Our results raise the possibility that
FANCD2 is regulated through proteolytic degradation triggered
by caspase 3 during DNA damage-induced apoptosis. Based on
the structural data [9], all of the cleavage sites we identiﬁed are
located on the outside surface of the FANCD2 protein, but not on
the interface involved in the FANCI interaction, suggesting that
caspase 3 can easily access these cleavage sites even in the context
of the ID complex. Furthermore, cleavage products from FANCD2(D2-XS) tended to accumulate in the presence of a proteasome
inhibitor (lactacystin) (Figs. 1C and S1). Because the z-VAD-fmk
treatment prevented the appearance of D2-XS even in the presence
of lactacystin, these results suggest that the FANCD2 protein is
cleaved ﬁrst by caspase 3 in an endolytic manner, and then further
degraded by the ubiquitin–proteasome system. However, we can-
not rule out an alternative model in which full-length FANCD2 is
also a target for the proteasome, because the level of endogenous
FANCD2 was slightly increased by lactacystin treatment (Fig. S1).
We also noticed that treatment with high doses of cisplatin
induced attenuation of full-length FANCD2, even in a cell line
expressing the FANCD2 4DA mutant, which does not undergo
apparent cleavage (Fig. 7A). This dose-dependent attenuation of
FANCD2 might arise from its proteolytic degradation via the
proteasome.
Although mono-ubiquitylation of FANCD2 is critical for down-
stream events of the canonical FA pathway [7], caspase-mediated
cleavage of FANCD2 does not depend on either the functional FA
core complex (Fig. 4A) or the lysine residue at the mono-ubiquity-
lation site (K561; Fig. 4B). On the other hand, our results showed
that functional p53 is not essential for FANCD2 cleavage, but acti-
vated p53 does promote the cleavage (Fig. 5). Another group
revealed that exogenous expression of FANCD2 induces apoptosis,
but not in cells lacking functional p53 [31], implicating FANCD2 in
p53-dependent apoptosis. FANCD2 cleavage in p53-deﬁcient cell
lines presumably reﬂects the activity of the p53-independent
apoptosis pathway. p53 is one of the most frequently mutated
genes in human tumors; therefore, an understanding of the molec-
ular mechanism underlying such an apoptotic pathway would be
clinically relevant, because the pathway components represent
potential therapeutic targets.
Amino-acid substitutions at FANCD2 cleavage sites did not
interfere with mono-ubiquitylation induced by DNA damage, the
ability to rescue the FANCD2-deﬁcient cell line’s sensitivity to ICL
damage, or the interaction with FANCI (Fig. 7), suggesting that
cleavage per se is not required for FANCD2 functions in DDRs
and/or DNA repair. Notably, however, nuclear foci formation was
seriously impaired in the cell line expressing caspase-resistant
FANCD2 (Figs. 7E and S3). Consistent with this, another group
reported that the FANCD2–ubiquitin fusion protein was competent
to mount a DDR but lacked the ability to form nuclear foci [8].
Taken together, these data suggest that nuclear foci formation by
FANCD2 is involved in a process other than DNA repair.
Fig. 7. Caspase 3-resistant FANCD2 is functional in DDR but defective in nuclear foci formation. (A) Four aspartic acid residues in FANCD2, identiﬁed as caspase target sites,
were simultaneously mutated to alanines. Wild-type FANCD2 and the quadruple mutant (4DA) were fused to the FLAG tag and stably expressed in the PD20F (parental) cell
line. Cells were treated with indicated concentrations of cisplatin for 24 h. Whole-cell extracts were subjected to immunoblotting with the indicated antibodies. (B) MMC
sensitivity of cells expressing caspase-resistant FANCD2. (C) Co-immunoprecipitation assay. Whole-cell extracts were prepared from cells treated with or without cisplatin
for 24 h, and subjected to immunoprecipitation with the anti-FLAG M2 magnetic beads. Co-precipitated proteins were detected by immunoblotting with the indicated
antibodies. I-L: mono-ubiquitylated FANCI, I-S: non-ubiquitylated FANCI. (D) Cleavage of PARP1 and activation of caspase 3 after treatment with cisplatin. The indicated cell
lines were treated with various concentrations of cisplatin for 24 h. Whole-cell extracts were subjected to immunoblotting with indicated antibodies. (E) Damage-induced
nuclear localizations of ectopically expressed wild-type FANCD2 and its 4DA mutant were visualized by immunoﬂuorescence microscopy following treatment with CDDP
(10 lM) for 36 h. cH2A.X immunostaining was used as a control to indicate that DNA damage had occurred. The bottom panel is a merged image of three channels: FANCD2
(green), cH2A.X (red), and DAPI staining (blue). Representative pictures of immunostained cells are shown. Scale bar, 10 lm.
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4DA mutant protein was slightly more resistant to MMC than the
control cell line expressing wild-type FANCD2 (Fig. 7B). Other
studies reported that caspase-mediated cleavage of DNA repair
proteins inhibited their functions as a suppressor of apoptosis
[18,22,23]. However, the 4DA mutations in FANCD2 seemed to
have little, if any, effect on apoptosis induction, judging from hall-
marks of apoptosis such as the appearance of cleaved PARP1 and
caspases (Fig. 7D). It is possible that protection of FANCD2 from
cleavage may be beneﬁcial for cell survival with sustained DNA
repair functions, although we cannot exclude the possibility thatthese amino-acid changes affect interactions with other proteins
involved in the DDR and/or apoptosis. Alternatively, acute
exposure to cisplatin may induce not only apoptosis, but also
non-apoptotic cell death such as necroptosis. Further studies of
FANCD2 cleavage will shed light on the possible effects of this
phenomenon on DNA damage-induced cell death.
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